Delivery Order SPE2DB22D2206-SPE2DB25FKD42
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of ONIVYDE 43 mg/10 ml vials valued at $5,345.67 with a firm fixed price structure. This non-set-aside delivery order is scheduled for ultimate completion by July 10, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of ONIVYDE 43 mg/10 ml vials, with a firm fixed price ceiling value of $10,691.34 and an ultimate completion date of October 8, 2025. This non-set-aside, competitively awarded delivery order is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of ONIVYDE 43 mg/10 mL vials. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $5,345.67 and is scheduled for completion by September 17, 2025. ONIVYDE is a chemotherapy medication used primarily in cancer treatment regimens. The award represents a child contract under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $10,691.34 to AmerisourceBergen Drug Corp for the supply of Onivyde 43 mg/10 ml vials on April 24, 2025, with an ultimate completion date of May 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Onivyde is a specialized oncology medication used in cancer treatment, reflecting...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $21,382.68 for ONIVYDE 43 mg/10 ml vials on August 12, 2025, with completion targeted for September 3, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. ONIVYDE (irinotecan liposome injection) is a specialized oncology medication used in cancer treatment protocols,...
- The Defense Logistics Agency awarded a delivery order valued at $10,691.34 to AmerisourceBergen Drug Corp for the supply of Onivyde 43 mg/10 ml vials on August 28, 2025, with an ultimate completion date of September 19, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Onivyde (irinotecan liposomal) 43 mg/10 mL vials at a ceiling value of $10,691.34. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract is scheduled for ultimate completion by October 1, 2025, and performance will be executed from AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for ONIVYDE 43 mg/10 ml vials, valued at $10,691.34 under a firm fixed price contract type. The award was made on September 23, 2025, with an ultimate completion date of October 15, 2025, and the work will be performed at the contractor's location in Conshohocken, Pennsylvania. This non-competitive delivery order draws from AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $10,691.34 delivery order to AmerisourceBergen Drug Corp for ONIVYDE 43 mg/10 mL vials on June 5, 2025, with completion targeted for June 27, 2025. ONIVYDE (irinotecan liposome injection) is a chemotherapy agent used in cancer treatment, reflecting the breadth of pharmaceutical products supplied through federal medical procurement channels. This non-competitive delivery order is priced on a firm fixed-price basis and will be performed at the vendor's...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ONIVYDE 43 MG/10 ML VIAL 10ML, a pharmaceutical product, with a ceiling value of $10,691.34 and a performance period ending on May 9, 2025. The contract is a firm-fixed-price delivery order, and it is not designated as a set-aside. AmerisourceBergen Drug Corp holds a larger...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FKD42Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 28, 2025, for the supply of ONIVYDE 43 mg/10 mL vials valued at $10,691.34. This is a firm fixed-price delivery order with an ultimate completion date of October 20, 2025, with performance to be completed at the vendor's Conshohocken, Pennsylvania location. The award represents a non-competitive, non-set-aside delivery order, indicating it was issued under an existing contract vehicle rather than through open competition. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply agreement running through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp supplies a wide range of medications and medical commodities to support military healthcare systems and other government agencies, including the Defense Health Agency and U.S. Coast Guard. The current delivery order for ONIVYDE, a specialized cancer treatment medication, reflects the company's role in supplying critical specialty pharmaceuticals to the Department of Defense medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 9/28/25 |